Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union

Barchart · 2d ago

Company plans to request re-examination following negative CHMP opinion for arimoclomol MAA

Zevra continues to support access to arimoclomol for eligible patients through its global Expanded Access Program

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.